Abstract
An overview of the application of markers for solid tumours is presented. Some of the potential problems with general cancer tests are considered as well as the ways in which the more specific markers have been applied. The limited specificities of markers defined so far remain a serious limitation but they have found useful clinical application. Their use in radioimmunolocalisation provides an interesting challenge to the physical methods of tumour localisation and the possibilities of drug targeting by antibodies are as exciting as the difficulties are formidable. It is, I suggest, a field that will continue to evolve and be productive.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Additional information
Delivered at the Joint Meeting of the British Association for Cancer Research & the Royal Society of Medicine (Section of Oncology), Nov. 39-Dec. 1. 1982.
Rights and permissions
About this article
Cite this article
Bagshawe, K. Third Gordon Hamilton-Fairley Memorial Lecture. Tumour markers—Where do we go from here?. Br J Cancer 48, 167–175 (1983). https://doi.org/10.1038/bjc.1983.172
Issue Date:
DOI: https://doi.org/10.1038/bjc.1983.172
This article is cited by
-
Antibody-directed enzyme prodrug therapy (ADEPT)
Cell Biophysics (1994)
-
In vitro and in vivo studies of the production of placental proteins (HCG, SP1, PPs) in human choriocarcinoma cell lines
Archives of Gynecology and Obstetrics (1987)
